Coronavirus: AstraZeneca to supply potential vaccine In September this year

[babu M]

AstraZeneca (AZN) confirmed that it will begin to supply a potential vaccine to battle the COVID-19 infection as of September this year.

The pharmaceutical giant said in a statementthat it has the capacity to manufacture one billion doses of the University of Oxford’s potential vaccine through 2020 and 2021 and it has already secured the first agreements for at least 400 million doses of the vaccine.

The new coronavirus has so far infected nearly five million people and killed more than 300,000 across the globe.

The vaccine, previously known as ChAdOx1 nCoV-19 but it now known as AZD1222, is being developed by the Jenner Institute and Oxford Vaccine Group at the University of Oxford.

AstraZeneca said it has now finalised its licence agreement with Oxford University for the “recombinant adenovirus vaccine.”

On 14 April, AstraZeneca said it would start a clinical trial to assess the potential of Calquence in the treatment of the exaggerated immune response associated with COVID-19 infection.

On 30 April, AstraZeneca and the University of Oxford announced that they had teamed up to make and distribute a potential coronavirus vaccination, as scientists across the world race to develop drugs to combat the pandemic.

There are more than 70 coronavirus vaccines currently in the works and a finished product could take more than a year to emerge. The usual lead time for the development of a vaccination is five to seven years.

The group also confirmed on Thursday that “today’s announcement is not anticipated to have any significant impact on the Company’s financial guidance for 2020; expenses to progress the vaccine are anticipated to be offset by funding by governments.”
(AZN) confirmed that it will begin to supply a potential vaccine to battle the COVID-19 infection as of September this year.

The pharmaceutical giant said in a statementthat it has the capacity to manufacture one billion doses of the University of Oxford’s potential vaccine through 2020 and 2021 and it has already secured the first agreements for at least 400 million doses of the vaccine.

The new coronavirus has so far infected nearly five million people and killed more than 300,000 across the globe.

The vaccine, previously known as ChAdOx1 nCoV-19 but it now known as AZD1222, is being developed by the Jenner Institute and Oxford Vaccine Group at the University of Oxford.

AstraZeneca said it has now finalised its licence agreement with Oxford University for the “recombinant adenovirus vaccine.”

On 14 April, AstraZeneca said it would start a clinical trial to assess the potential of Calquence in the treatment of the exaggerated immune response associated with COVID-19 infection.

On 30 April, AstraZeneca and the University of Oxford announced that they had teamed up to make and distribute a potential coronavirus vaccination, as scientists across the world race to develop drugs to combat the pandemic.

There are more than 70 coronavirus vaccines currently in the works and a finished product could take more than a year to emerge. The usual lead time for the development of a vaccination is five to seven years.

The group also confirmed on Thursday that “today’s announcement is not anticipated to have any significant impact on the Company’s financial guidance for 2020; expenses to progress the vaccine are anticipated to be offset by funding by governments.”
(AZN) confirmed that it will begin to supply a potential vaccine to battle the COVID-19 infection as of September this year.

The pharmaceutical giant said in a statementthat it has the capacity to manufacture one billion doses of the University of Oxford’s potential vaccine through 2020 and 2021 and it has already secured the first agreements for at least 400 million doses of the vaccine.

The new coronavirus has so far infected nearly five million people and killed more than 300,000 across the globe.

The vaccine, previously known as ChAdOx1 nCoV-19 but it now known as AZD1222, is being developed by the Jenner Institute and Oxford Vaccine Group at the University of Oxford.

AstraZeneca said it has now finalised its licence agreement with Oxford University for the “recombinant adenovirus vaccine.”

On 14 April, AstraZeneca said it would start a clinical trial to assess the potential of Calquence in the treatment of the exaggerated immune response associated with COVID-19 infection.

On 30 April, AstraZeneca and the University of Oxford announced that they had teamed up to make and distribute a potential coronavirus vaccination, as scientists across the world race to develop drugs to combat the pandemic.

There are more than 70 coronavirus vaccines currently in the works and a finished product could take more than a year to emerge. The usual lead time for the development of a vaccination is five to seven years.

The group also confirmed on Thursday that “today’s announcement is not anticipated to have any significant impact on the Company’s financial guidance for 2020; expenses to progress the vaccine are anticipated to be offset by funding by governments.”

 

[Zero Hours]

Gud

Sent using Jamii Forums mobile app

 

[mkulu senkondo]

Once the problem already created, manifested and promoted; the next step is to introduce solution that will ensure wealth accumulation worldwide.

 

[Bia yetu]

Potential vaccine ?

 

[denooJ]

Hii vaccine Oxford University imeshakuwa approved by WHO, sioni popote panapothibitisha hilo?

Naona hapo chini wanasema "there are more than 70 CoronaVirus vaccines currently in the works, and a usual product could take more than a year to emerge" je, hii vaccine ya Oxford imesha take more than a year?

Naona hao jamaa wapo kibiashara zaidi, nothing else.

Sent using Jamii Forums mobile app

 

[babu M]

Potential vaccine ?

Kwa sababu bado ipo kwenye trial process lakini imeonyesha matumaini makubwa!

 

[Viol]

September mbali sana

 

[Bia yetu]

Thera are more than 70 corona vaccine currently in the works...

Katika hii sentensi dawa za kiafrica zipo katika orodha?

 

[Bia yetu]

Kwa sababu bado ipo kwenye trial process lakini imeonyesha matumaini makubwa!

Jibu hapa

Thera are more than 70 corona vaccine currently in the works...

Katika hii sentensi dawa za kiafrica zipo katika orodha?

 

[Bana likasi]

Hii ya jamaa wa kibaha imethibitishwa na Nimri inatibu na ni Kinga pia bei nafuu ya kitanzania 0785 355 551

 

[nguruka wa kig0ma]

Jibu hapa

Nilichokihisi kuwa bia yao, ni punguani kumbe kweli.
Peleka wewe ikaorodheshwe, yeye amekupa taarifa

Sent using Jamii Forums mobile app

 

[Erythrocyte]

Mungu wabariki wazungu

 

[Bia yetu]

Nilichokihisi kuwa bia yao, ni punguani kumbe kweli.
Peleka wewe ikaorodheshwe, yeye amekupa taarifa

Sent using Jamii Forums mobile app

Chadema mlizaliwa na matusi ?

 

[babu M]

Hii vaccine Oxford University imeshakuwa approved by WHO, sioni popote panapothibitisha hilo?

Naona hapo chini wanasema "there are more than 70 CoronaVirus vaccines currently in the works, and a usual product could take more than a year to emerge" je, hii vaccine ya Oxford imesha take more than a year?

Naona hao jamaa wapo kibiashara zaidi, nothing else.

Sent using Jamii Forums mobile app

Hizi Vaccine/drug approval inatolewa na nchi husika. Mfano UK hawa AstraZeneca inabidi wawe approve na MHRA na kama ni USA ni FDA.
Nchi husika ndio zenye mamlaka kwenye approval na sio WHO.

Kuna makampuni mengi dunia yapo kwenye mbio za kutafuta Vaccine au Antivirals. Kuna ambayo yanafanya majaribio ya dawa ambazo zimeshatumiwa kwenye magonjwa mengine kama Ebola, malaria na kadhalika.

Lakini kuna big Pharmas ambazo wapo kwenye clinical trials na zimeonyesha matokeo mazuri. Mfano:
Sanofi(France)
AstraZeneca(UK)
Gilead (US)
Moderna(US)

Moderna wao wametoa tamko wiki hii kuhusu dawa yao ambayo ilichangia kampuni yao kupanda thamani kwenye soko la hisa.

 

[babu M]

Jibu hapa

Nimeshajibu kwenye posti nyingine.
Kwa kifupi yapo makampuni (Pharmas) ambazo wana vaccines au antivirals zipo kwenye clinical trials lakini inabidi wapate kibali(approval) kwenye nchi husika kuruhusu kutumika mahospitalini na majumbani.

 

[babu M]

AstraZeneca receives $1 billion in US funding for Oxford University coronavirus vaccine


AstraZeneca has received more than $1 billion from the U.S. Health Department's Biomedical Advanced Research and Development Authority (BARDA) to develop a coronavirus vaccine from the University of Oxford.

The British-Swedish drugmaker has agreed to initially supply at least 400 million doses of the vaccine and secured total manufacturing capacity to produce 1 billion doses, with first deliveries in September.

AstraZeneca's development program of the vaccine includes a phase three clinical trial with 30,000 participants and a pediatric trial.

Pascal Soriot, CEO of AstraZeneca, said the drugmaker would do everything in its power to make the vaccine "quickly and widely available."

The coronavirus has now infected over 5 million and killed 328,227 people worldwide, according to data compiled by Johns Hopkins University.

On Sunday, the British government announced it was putting £65.5 million ($79 million) in fresh funding toward the development of the Covid-19 vaccine, with 30 million doses expected to be rolled out as early as September.

The University of Oxford announced it had partnered with AstraZeneca in April, to allow the drugmaker to develop and distribute the vaccine being researched by the Jenner Institute and Oxford Vaccine Group.

Human trials began last month on over 1,000 volunteers in the south of England and AstraZeneca said in this latest announcement that data from the trials was "expected shortly which, if positive, would lead to late-stage trials in a number of countries."

Although, given that no trial data has been released, we do not yet know if the vaccine will be effective and AstraZeneca has said it recognizes that it may not work.

On Monday, U.S. drugmaker Moderna released positive data from its phase one human trial on its potential vaccine, in development with the U.S. government.

Health-care publication STAT then reported Tuesday that vaccine experts were skeptical of Moderna's new data. However, Moderna Chairman Noubar Afeyan told CNBC Wednesday that the drugmaker would never put out coronavirus vaccine data that was different from "reality."

Moderna said earlier in May that it was wrapping up the phase one trials and was moving to start phase two trials, expecting phase three to begin in July. If the vaccine was found to be safe to use, Moderna said it could be ready for the market in early 2021.

BARDA has also provided funding for one of the two vaccines being developed by French pharmaceuticals company Sanofi, which it is working on with U.K. drugmaker GlaxoSmithKline, according to Reuters in a report which said there are more than 90 vaccines being developed around the world, with eight in clinical trials.